Published in Proc Natl Acad Sci U S A on May 01, 1978
Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin Microbiol Rev (1996) 2.14
Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumtol (2011) 0.98
Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol (2010) 0.95
Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity (2008) 0.93
Detection and quantification of type C viral proteins in tissues and sera with an enzyme immunoassay. Infect Immun (1980) 0.85
Evidence in patients with systemic lupus erythematosus of the presence of antibodies against RNA-dependent DNA polymerase of baboon endogenous virus. Clin Exp Immunol (1983) 0.82
Detection and immunochemical characterization of a primate type C retrovirus-related p30 protein in normal human placentas. Proc Natl Acad Sci U S A (1984) 0.81
Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol (1972) 40.51
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
A proposed nomenclature for the virion proteins of oncogenic RNA viruses. Virology (1974) 5.01
Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus. J Immunol (1969) 4.45
SPECIFIC COMPLEMENT-FIXING VIRAL ANTIGENS IN HAMSTER AND GUINEA PIG TUMORS INDUCED BY THE SCHMIDT-RUPPIN STRAIN OF AVIAN SARCOMA. Proc Natl Acad Sci U S A (1964) 4.42
Further implication of murine leukemia-like virs in the disorders of NZB mice. J Exp Med (1969) 3.87
The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J Exp Med (1974) 3.53
Detection of avian and mammalian oncogenic RNA viruses (oncornaviruses) by immunofluorescence. Cancer Res (1972) 3.23
Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen. Arthritis Rheum (1974) 2.99
Type C RNA tumor virus isolated from cultured human acute myelogenous leukemia cells. Science (1975) 2.92
Radioimmunoassay of mammalian type-C viral proteins: interspecies antigenic reactivities of the major internal polypeptide. Proc Natl Acad Sci U S A (1972) 2.90
Coexistence of intraspecies and interspecies specific antigenic determinants on the major structural polypeptide of mammalian C-type viruses. Nat New Biol (1971) 2.70
RNA in human leukemic cells related to the RNA of a mouse leukemia virus (leukocytes-RNA-DNA hybridization-rauscher virus-polysomal RNA). Proc Natl Acad Sci U S A (1972) 2.55
Isolation of type C virions from a normal human fibroblast strain. Science (1975) 2.52
Isolation of infectious C-type oncornavirus from human leukaemic bone marrow cells. Nature (1975) 2.22
Species-specific and interspecific antigenic determinants associated with the structural protein of feline C-type virus. Proc Natl Acad Sci U S A (1971) 2.20
Polynucleotide immune complexes in serum and glomeruli of patients with systemic lupus erythematosus. Am J Pathol (1974) 2.12
Evolution of type C viral genes: I. Nucleic acid from baboon type C virus as a measure of divergence among primate species. Proc Natl Acad Sci U S A (1974) 2.03
Shared group-specific antigen of murine and feline leukemia viruses. Virology (1968) 1.78
Interspecies antigenic determinants of the reverse transcriptases and p30 proteins of mammalian type C viruses. J Virol (1975) 1.64
Radioimmunoassay of the major group specific protein of endogenous baboon type C viruses: relation to the RD-114-CCC group and detection of antigen in normal baboon tissues. Virology (1974) 1.46
Expression of endogenous RNA C-type virus group-specific antigens in mammalian cells. J Virol (1973) 1.45
Type-C RNA virus gene expression in human tissue. J Virol (1974) 1.26
Immune complex disease in the kidneys of lymphoma-leukemia patients: the presence of an oncornavirus-related antigen. J Natl Cancer Inst (1973) 1.23
C-type viruses in systemic lupus erythematosus. Nature (1974) 1.19
Antigen related to mammalian type-C RNA viral p30 proteins is located in renal glomeruli in human systemic lupus erythematosus. Proc Natl Acad Sci U S A (1976) 1.18
Natural human antibodies reactive with primate type-C viral antigens. Proc Natl Acad Sci U S A (1977) 1.12
Structural proteins of mammalian RNA tumor viruses: relatedness of the interspecies antigenic determinants of the major internal protein. J Virol (1975) 1.06
Natural antibodies in sera from healthy humans to antigens on surfaces of type C RNA viruses and cells from primates. Proc Natl Acad Sci U S A (1976) 1.05
Search for antigens and antibodies crossreactive with type C viruses of the woolly monkeys and gibbon ape in animal models and in humans. Proc Natl Acad Sci U S A (1976) 1.04
Immunochemical studies of the major internal polypeptide of woolly monkey and gibbon ape type C viruses. J Immunol (1974) 1.03
Type C viral antigens in man. I. Antigens related to endogenous primate virus in human tumors. Proc Natl Acad Sci U S A (1974) 1.00
Specificities of human immunoglobulins reactive with antigens in preparations of several mammalian type-C viruses. Virology (1976) 1.00
Primate type-C virus nucleic acid sequences (woolly monkey and baboon types) in tissues from a patient with acute myelogenous leukemia and in viruses isolated from cultured cells of the same patient. Proc Natl Acad Sci U S A (1976) 1.00
C-type virus expression in systemic lupus erythematosus. N Engl J Med (1976) 0.97
Failure to detect, in human sera, antibodies cross-reactive with group-specific antigens of murine leukemia virus. J Natl Cancer Inst (1974) 0.94
Antibodies in human sera to oncorna virus-like proteins from normal or leukemia marrow cell cultures. J Exp Med (1976) 0.82
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Immunopathology of NZB/BL mice. V. Viruslike (filtrable) agent separable from lymphoma cells and identifiable by electron microscopy. J Exp Med (1966) 4.19
Further implication of murine leukemia-like virs in the disorders of NZB mice. J Exp Med (1969) 3.87
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J Exp Med (1974) 3.53
Natural thymocytotoxic autoantibody and reactive antigen in New Zealand black and other mice. Proc Natl Acad Sci U S A (1971) 3.50
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Immunopathology of NZB/BL mice. VI. Virus separable from spleen and pathogenic for Swiss mice. J Exp Med (1967) 2.53
Autoimmune disease in NZB-Bl mice. II. Autoimmunity and malignant lymphoma. Blood (1966) 2.51
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Wild-type Gross leukemia virus and the pathogenesis of the glomerulonephritis of New Zealand mice. J Exp Med (1971) 2.41
A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother (1997) 2.22
Autoimmune and immunoproliferative diseases of NZB/Bl mice and hybrids. Int Rev Exp Pathol (1966) 2.01
THE REGENERATIVE CYCLE OF MOTONEURONS, WITH SPECIAL REFERENCE TO PHOSPHATASE ACTIVITY. J Exp Med (1945) 1.97
Biological expression of antigenic determinants of murine leukemia virus proteins gp69-71 and p30. J Virol (1974) 1.95
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol (2004) 1.87
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
Common cell surface antigen associated with mammalian C-type RNA viruses. Cell membrane-bound gs antigen. J Exp Med (1974) 1.61
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA (1998) 1.59
Infrared Spectra of Tissues. Science (1949) 1.39
Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J Virol (2000) 1.38
CYTOCHROME OXIDASE IN NORMAL AND REGENERATING NEURONS. J Exp Med (1945) 1.37
Natural history of HIV-1 infection. Infect Dis Clin North Am (2000) 1.34
Natural cytotoxic autoantibody against thymocytes in NZB mice. Clin Exp Immunol (1972) 1.34
Thymus dependence of cells in peripheral lymphoid tissues and in the circulation sensitive to natural thymocytotoxic autoantibody in NZB mice. J Immunol (1972) 1.32
Changes in lymphoid populations of ageing CBA and NZB mice. Clin Exp Immunol (1971) 1.31
Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis (1999) 1.28
Autoimmune disease in NZB/BL mice. 3. Induction of membranous glomerulonephritis in young mice by the transplantation of spleen cells from old mice. J Exp Med (1966) 1.24
HIV-1 viral dynamics and viral load measurement: implications for therapy. AIDS Clin Rev (1997) 1.20
Common cell-surface antigen associated with murine and feline C-type RNA leukemia viruses. Proc Natl Acad Sci U S A (1973) 1.20
Antigen related to mammalian type-C RNA viral p30 proteins is located in renal glomeruli in human systemic lupus erythematosus. Proc Natl Acad Sci U S A (1976) 1.18
Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrob Agents Chemother (2001) 1.16
Age-decrease of cells sensitive to an autoantibody-specific for thymocytes and thymus-dependent lymphocytes in NZB mice. Clin Exp Immunol (1972) 1.14
Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J Immunol (1987) 1.11
Wild-type Gross leukemia virus and heritable autoimmune disease of New Zealand mice. Am J Clin Pathol (1971) 1.09
Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood (1988) 1.09
The occurrence and frequency of type C virus-like particles in placentas from patients with systemic lupus erythematosus and from normal subjects. Am J Pathol (1976) 1.09
Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrob Agents Chemother (1994) 1.08
Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol (1999) 1.07
Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir Ther (1999) 1.04
Use of recombinant retroviruses to characterize the activity of antiretroviral compounds. J Virol (1991) 1.04
Arteriolization of venous blood gases: a clue to the diagnosis of cyanide poisoning. J Emerg Med (1989) 1.02
Murine leukemialike virus and the immunopathologic disorders of New Zealand black mice. J Infect Dis (1969) 1.00
IgG anti-cardiolipin antibodies in murine lupus. Clin Exp Immunol (1989) 0.99
Assay and characterization of polyanion--immunoglobulin complexes in sera of New Zealand Black mice. Immunology (1974) 0.96
Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med (1997) 0.96
Effects of natural thymocytotoxic autoantibody of NZB mice and of specifically prepared antilymphocyte serum on the tissue distribution of 51 Cr-labeled lymphocytes. J Immunol (1973) 0.94
Electron microscopic study of distinctive structures in peripheral blood lymphocytes obtained from twins with systemic lupus erythematosus. Am J Pathol (1975) 0.93
HIV-1 viral load and clinical outcome: review of recent studies. AIDS (1997) 0.93
Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Res (1993) 0.92
The application of labeled antibody technics in studying cell antigens. Cancer Res (1968) 0.92
CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects. Clin Diagn Lab Immunol (2000) 0.91
A simple index to identify occult bacterial infection in adults with acute unexplained fever. Arch Intern Med (1987) 0.90
Immunologic observations on 9 sets of twins either concordant or discordant for SLE. Arthritis Rheum (1976) 0.89
Pasteurella multocida septic arthritis. Conn Med (1984) 0.89
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples. Adv Virol (2011) 0.87
Prospects for the Biological Control of Cancer. Bull N Y Acad Med (1962) 0.86
Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. Antivir Ther (2001) 0.86
The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Transfusion (1996) 0.86
Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. AIDS Res Hum Retroviruses (2001) 0.84
Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res (1995) 0.84
Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate. Biochem Pharmacol (1998) 0.83
Interleukin-6 expression in primary macrophages infected with human immunodeficiency virus-1 (HIV-1). AIDS Res Hum Retroviruses (1991) 0.83
Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis (1996) 0.82
Murine Type C viral envelope glycoprotein gp69/71 and lupus-like glomerulonephritis of New Zealand mice. An immunoperoxidase study. Am J Pathol (1977) 0.82
Immunohistologic detection of antigen related to primate type C retrovirus p30 in normal human placentas. Am J Pathol (1983) 0.81
Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1999) 0.81
Acute human immunodeficiency virus infection: false-negative ELISA in a patient with viremia and a positive western blot test. J Infect Dis (1989) 0.81
Detection and immunochemical characterization of a primate type C retrovirus-related p30 protein in normal human placentas. Proc Natl Acad Sci U S A (1984) 0.81
Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1998) 0.80
In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine. Antivir Chem Chemother (2000) 0.80
Immunocytes and immunoglobulins. Blood (1966) 0.80
Value of the serum bactericidal test in management of patients with bacterial endocarditis. Eur J Clin Microbiol (1986) 0.80
Tryptic peptide analysis of gag gene proteins of endogenous mouse type C viruses. J Virol (1979) 0.79
Adefovir for the treatment of HIV infection: if not now, when? JAMA (1999) 0.79
Sanctuary growth of human immunodeficiency virus in the presence of 3'-azido-3'-deoxythymidine. J Virol (1995) 0.79
Pasteurella multocida prosthetic joint infection. Ann Emerg Med (1985) 0.78
Prevalence of XMRV nucleic acid and antibody in HIV-1-Infected men and in men at risk for HIV-1 Infection. Adv Virol (2011) 0.78
Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A. Infect Immun (1989) 0.77
Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. Ann Intern Med (1996) 0.77
Effective salvage therapy for HIV-1 infection--an unmet challenge. Antivir Ther (1999) 0.77
Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. Antimicrob Agents Chemother (1992) 0.77
Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med (1985) 0.76
Leukemia serum reactive with retrovirus-related antigen in normal human placenta. Int J Cancer (1986) 0.76
FLUID, PROTEIN AND ELECTROLYTE ALTERATIONS IN EXPERIMENTAL INTESTINAL OBSTRUCTION. Ann Surg (1943) 0.75
Antiretroviral therapy for previously treated patients. N Engl J Med (2001) 0.75
Diagnosis and treatment of urethritis in men. Yale J Biol Med (1983) 0.75